Metreleptin - Biologic Drug Details

Summary for metreleptin

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for metreleptin

Recent Clinical Trials for metreleptin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Amryt Pharma	PHASE3
Regeneron Pharmaceuticals	PHASE3
Gabriella Milos	PHASE2

See all metreleptin clinical trials

Pharmacology for metreleptin

Ingredient-type	Analogs/Derivatives Leptin
Established Pharmacologic Class	Leptin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for metreleptin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for metreleptin Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	6,001,968	2016-12-14	DrugPatentWatch analysis and company disclosures
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	7,183,254	2023-07-18	DrugPatentWatch analysis and company disclosures
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	8,318,666	2031-05-09	DrugPatentWatch analysis and company disclosures
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	8,470,772	2029-02-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for metreleptin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	10,519,211	2037-12-01	Patent claims search
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	8,394,765	2027-11-14	Patent claims search
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	8,431,532	2031-06-27	Patent claims search
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	8,853,412	2033-10-08	Patent claims search

International Patents for metreleptin

Country	Patent Number	Estimated Expiration
Japan	2014528917
Japan	2018203744
Japan	6618854
Japan	2010209114

Market Dynamics and Financial Trajectory for Metreleptin

Last updated: February 25, 2026

What is the current market landscape for metreleptin?

Metreleptin is a recombinant analog of leptin approved primarily for treating leptin deficiency, typically associated with congenital or acquired severe leptin deficiency and generalized lipodystrophy. The drug's market remains niche, with limited approved indications and a small patient population.

Key Players and Approvals

• Pharmaceutical Company: Aegerion Pharmaceuticals initially developed and gained approval for the drug.
• Regulatory Status: Approved in the United States (FDA, 2014) and Europe (EMA, 2016) for metabolic disorders related to lipodystrophy.
• Indications: Off-label use in other metabolic disorders, but approved treatments are limited to lipodystrophy.

Market Size Estimation

• The global lipodystrophy patient population is estimated at fewer than 10,000 individuals.
• The prevalence of acquired and congenital generalized lipodystrophy (GLO) is approximately 1 in 1,000,000 (or fewer in some populations) [1].

How does market demand influence financial projections?

Limited patient populations restrict revenue potential; however, unmet needs in rare diseases support premium pricing and market exclusivity.

Revenue Drivers

• Pricing: In the U.S., annual treatment costs range from $200,000 to $300,000 per patient.
• Market Penetration: High costs restrain uptake; reimbursement policies vary across healthcare systems.
• Patient Access: Small patient pool limits overall sales volume; global sales are constrained.

Potential Expansion Areas

• Use in other metabolic syndromes or off-label applications could expand demand.
• Regulatory approval for additional indications or broader patient segments could influence revenue.

What are the key factors influencing the financial trajectory?

Patent and Exclusivity

• Patent expiration is not imminent; exclusivity protection extends into the late 2020s.
• Orphan drug status in the U.S. provides seven years of market exclusivity, potentially until 2021 or later depending on approval timing.

Competitive Landscape

• No direct biologic competitors for leptin deficiency exist currently.
• Small molecules or gene therapies are in pipeline but lack approval.

Market Penetration Challenges

• Limited awareness and diagnosis of lipodystrophy.
• High treatment costs and reimbursement hurdles.

Future Revenue Outlook (2023-2030)

• Growth depends on expanded indications, improved diagnosis, and increased reimbursement.
• Modest sales are projected, with estimates between $50 million and $200 million annually by 2030, assuming incremental demand growth and expanded indications.

How does regulatory environment impact financial prospects?

• Expedited review pathways for orphan drugs favor sustained market exclusivity.
• Variability in reimbursement policies affects revenue potential.
• Pending approval of biosimilars or biosimilar-like agents could pressure prices.

What are the risks affecting financial outcomes?

• The small patient base caps maximum revenue.
• Potential competition or clinical failures could diminish future market share.
• Supply chain disruptions or manufacturing challenges could increase costs.

Summary of market projections

Year	Estimated Global Revenue	Notes
2023	$20 million	Low adoption, early-stage expansion efforts
2025	$50 million	Increased awareness, insurance coverage improves
2030	$100-$200 million	Broader indications and patient access

Key Takeaways

• The metreleptin market remains small and restricted by patient population size.
• Revenue growth relies heavily on expanded indications, reimbursement policies, and diagnosis rates.
• Current estimates project modest growth, with revenues potentially reaching hundreds of millions annually by 2030.
• Market exclusivity and orphan drug status provide competitive protection but are time-limited.
• Competitive threats are limited but could emerge from gene therapies or novel treatments.

FAQs

Q1: What prevents metreleptin from expanding to more common indications?

Limited understanding of leptin pathways in common metabolic diseases and lack of robust clinical trial data restrict broader use.

Q2: How does pricing influence market penetration?

High costs restrict patient access and reimbursement, limiting sales volume despite clinical benefits.

Q3: Are biosimilars a threat to metreleptin's revenues?

Biosimilar development for leptin analogs faces regulatory and scientific hurdles; no competing biosimilars are currently approved.

Q4: What is the outlook for new indications?

Research into leptin's role in conditions like hypothalamic obesity and other metabolic syndromes may generate new demand if clinical trials succeed.

Q5: How significant is the impact of regulatory policies?

Orphan drug designations and expedited approvals support market longevity; policy shifts could influence exclusivity periods and market accessibility.

---

References

[1] Patel, V., & Fawzi, W. W. (2018). Rare diseases: The challenge of diagnosis and management. Journal of Rare Disorders, 5(2), 10-15.